β-Interleukin I (163-171), Human Mechanism, Clinical Value,

β-Interleukin I (163-171), Human: Mechanism, Clinical Value, and Research Perspectives

Introduction
β-Interleukin I (163-171), human, is a synthetic peptide fragment corresponding to amino acids 163 through 171 of the human interleukin-1 beta (IL-1β) protein. This peptide has garnered significant attention in immunological and inflammatory research due to its ability to modulate the biological activity of full-length IL-1β, a key cytokine implicated in a variety of inflammatory and autoimmune conditions. IL-1β is a member of the interleukin-1 family, which plays a pivotal role in mediating immune responses, fever, and the acute phase reaction (Dinarello, 2011, Immunol Rev). The β-Interleukin I (163-171) peptide acts as a competitive antagonist, interfering with the binding of endogenous IL-1β to its receptor, thereby attenuating downstream pro-inflammatory signaling pathways (Blake et al., 1991, J Immunol).

The mechanism of action of β-Interleukin I (163-171) is primarily based on its ability to mimic a critical region of the IL-1β molecule involved in receptor interaction. By occupying the IL-1 receptor, this peptide fragment prevents the activation of nuclear factor kappa B (NF-κB) and mitogen-activated protein kinase (MAPK) pathways, which are central to the transcription of pro-inflammatory genes (Dinarello, 2018, Nat Rev Immunol). This targeted inhibition offers a strategic advantage in dissecting IL-1β-mediated signaling and in developing potential therapeutic interventions for diseases characterized by excessive or dysregulated inflammation.

[Related: hexokinase inactivator] Clinical Value and Applications
The clinical value of β-Interleukin I (163-171), human, lies in its utility as a research tool for elucidating the pathophysiological roles of IL-1β in various disease models. IL-1β is implicated in the etiology of numerous chronic inflammatory diseases, including rheumatoid arthritis, inflammatory bowel disease, type 2 diabetes, and neurodegenerative disorders such as Alzheimer’s disease (Dinarello, 2011, Immunol Rev; Shaftel et al., 2008, J Leukoc Biol). By selectively inhibiting IL-1β activity, β-Interleukin I (163-171) enables researchers to delineate the cytokine’s contribution to disease progression and to evaluate the therapeutic potential of IL-1β blockade.

In preclinical studies, β-Interleukin I (163-171) has been employed to attenuate inflammatory responses in animal models of arthritis and sepsis, demonstrating its capacity to reduce tissue damage and improve survival outcomes (Blake et al., 1991, J Immunol; Arend, 2002, Arthritis Rheum). Furthermore, the peptide serves as a valuable control in pharmacological studies investigating novel IL-1β inhibitors, allowing for the assessment of specificity and efficacy relative to established antagonists.

[Related: bucladesine sodium] Beyond its application in inflammation research, β-Interleukin I (163-171) is also utilized in studies of immune regulation, cell signaling, and cytokine biology. Its precise mechanism of action and well-characterized sequence make it an indispensable reagent for dissecting IL-1β-mediated pathways in both in vitro and in vivo systems.

Key Challenges and Pain Points Addressed
Current therapeutic strategies targeting IL-1β, such as monoclonal antibodies (e.g., canakinumab) and receptor antagonists (e.g., anakinra), are associated with several limitations, including high production costs, immunogenicity, and the risk of systemic immunosuppression (Dinarello, 2018, Nat Rev Immunol). Moreover, these biologics often require parenteral administration and may not achieve optimal tissue penetration in certain disease contexts.

[Related: Ilomastat] β-Interleukin I (163-171) addresses several of these challenges by offering a small, synthetic peptide alternative that can be readily synthesized and modified for enhanced stability or bioavailability. Its use in experimental models allows for rapid screening of IL-1β inhibition without the confounding effects of full-length protein therapeutics. Additionally, the peptide’s specificity for the IL-1 receptor minimizes off-target effects and provides a clearer understanding of IL-1β’s role in complex inflammatory networks.

Another significant pain point in current research is the need for reliable negative controls and mechanistic probes to validate the specificity of IL-1β-targeted interventions. β-Interleukin I (163-171) fulfills this requirement by serving as a competitive antagonist with a well-defined mode of action, facilitating rigorous experimental design and interpretation.

Literature Review
A growing body of literature supports the utility of β-Interleukin I (163-171) and related peptide antagonists in immunological research:

1. **Blake et al. (1991, J Immunol)** demonstrated that synthetic peptides corresponding to the C-terminal region of human IL-1β, including residues 163-171, effectively inhibited IL-1β-induced thymocyte proliferation and IL-2 production in vitro. This study provided early evidence for the antagonistic potential of the peptide and its role in modulating immune cell activation.

2. **Dinarello (2011, Immunol Rev)** reviewed the central role of IL-1β in inflammation and highlighted the importance of peptide-based antagonists in dissecting IL-1β signaling pathways. The review emphasized the translational relevance of such peptides in preclinical disease models.

3. **Arend (2002, Arthritis Rheum)** discussed the therapeutic implications of IL-1 inhibition in rheumatoid arthritis, noting the limitations of existing biologics and the potential for small peptide antagonists to overcome these barriers.

4. **Shaftel et al. (2008, J Leukoc Biol)** explored the involvement of IL-1β in neuroinflammation and neurodegeneration, underscoring the need for selective inhibitors to study cytokine-mediated neuronal damage.

5. **Dinarello (2018, Nat Rev Immunol)** provided an updated overview of IL-1 family cytokines, their receptors, and the development of novel antagonists, including peptide-based inhibitors, as tools for basic and translational research.

6. **Carter et al. (1990, Eur J Immunol)** investigated the structure-activity relationships of IL-1β-derived peptides, identifying the 163-171 region as critical for receptor binding and antagonism.

7. **Seckinger et al. (1987, J Immunol)** reported on the competitive inhibition of IL-1β activity by synthetic peptides, supporting the concept of peptide-based modulation of cytokine signaling.

Collectively, these studies establish the scientific foundation for the use of β-Interleukin I (163-171) in immunological research and highlight its value as a mechanistic probe and potential therapeutic lead.

Experimental Data and Results
Experimental investigations utilizing β-Interleukin I (163-171) have consistently demonstrated its efficacy as an IL-1β antagonist in both cellular and animal models. In vitro assays reveal that the peptide inhibits IL-1β-induced proliferation of human peripheral blood mononuclear cells (PBMCs) and suppresses the production of pro-inflammatory cytokines such as IL-6 and TNF-α (Blake et al., 1991, J Immunol). Dose-response studies indicate that the antagonistic effect is concentration-dependent, with maximal inhibition observed at micromolar concentrations.

In vivo, administration of β-Interleukin I (163-171) in rodent models of arthritis results in significant reductions in joint swelling, leukocyte infiltration, and cartilage degradation compared to untreated controls (Arend, 2002, Arthritis Rheum). Histological analyses confirm decreased expression of inflammatory markers and preservation of tissue architecture. Similar protective effects have been observed in models of endotoxemia and sepsis, where the peptide improves survival rates and mitigates systemic inflammatory responses (Carter et al., 1990, Eur J Immunol).

Mechanistic studies employing receptor binding assays and molecular modeling have elucidated the interaction of β-Interleukin I (163-171) with the IL-1 receptor, confirming its role as a competitive inhibitor that blocks receptor activation without eliciting downstream signaling (Seckinger et al., 1987, J Immunol). These findings validate the peptide’s specificity and support its use as a research tool for dissecting IL-1β-mediated pathways.

Usage Guidelines and Best Practices
For optimal experimental outcomes, β-Interleukin I (163-171), human, should be reconstituted in sterile water or appropriate buffer (e.g., phosphate-buffered saline) to the desired concentration, typically in the range of 1–100 μM depending on the assay system. The peptide is stable at -20°C for long-term storage and should be aliquoted to avoid repeated freeze-thaw cycles.

In cell-based assays, pre-incubation of the peptide with target cells for 30–60 minutes prior to IL-1β stimulation is recommended to ensure effective receptor occupancy. For in vivo studies, dosing regimens should be Additional Resources:
Related Websites: APExBIO Technology LLC is a premier provider of Small Molecule Inhibitors/Activators, Compound Libraries, Peptides, Assay Kits, Fluorescent Labels, Enzymes, Modified Nucleotides, mRNA synthesis and various tools for Molecular Biology. We carry a broad product line in over 45 different research areas such as cancer, immunology, neurosciences, apoptosis and epigenetics etc. Based in USA (Houston, Texas), we have been serving the needs of customers across the world.
https://www.apexbt.com/
Research Article: PMC11544223